Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of momelotinib that characterized its long-term safety, with pooled data from the three trials, which represented a spectrum of myelofibrosis disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages.
The abstract entitled ‘Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)’ (Abstract #4348) was presented at 64th ASH Annual Meeting and Exposition, December 10-13 2022, New Orleans, LA, USA
- What are the current limitations of JAK inhibitor therapy in myelofibrosis, and how does the mechanism of action of momelotinib potentially overcome these limitations? (0:12)
- Could you give us a brief overview of the SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM clinical trials in patients with high- and intermediate-risk myelofibrosis? (2:27)
- What do you see as the future of JAK inhibitors in myelofibrosis? (4:54)
Disclosures: Srdan Verstovsek has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
